Economy

Heraeus cooperates with Locate Therapeutics in Orthopedics

Heraeus Medical GmbH announced today an agreement with Locate Therapeutics to license the intellectual property surrounding the use of Taos in orthopaedic applications and the inception of the first development program in this field.

The agreement gives Heraeus Medical GmbH the rights to the future co-developed orthopaedic products as well as the processes involved in manufacturing the final product. Locate Therapeutics has the full capabilities to carry out such development work. The agreement takes the form of a standard upfront and milestone payment structure.

Locate is a specialist regenerative medicine and device company which has been incubated by University of Nottingham. With grant funding and financial assistance from Wellcome Trust and the Technology Strategy Board (now Innovate UK) the company has developed Taos a patented platform polymer technology with multiple medical applications. The Taos (Targeted, Orchestrated Signaling) technology is a world first in tissue repair. It enables the precision focus of therapeutic signals and provides an optimal structure to support tissue repair. Uniquely, Taos can accommodate and promote the actions of receptor-binding moieties, locally-applied drugs, and emergent biological & cell-based therapies.

“Regenerative orthopaedics solutions is an important part of Heraeus Medical`s future portfolio strategy. Locate Therapeutics has the expertise, technical capabilities and intellectual property to allow us to make an accelerated step into this exciting field of medicine and to strengthen our current regenerative product pipeline”, said Dr André Kobelt, CEO of Heraeus Medical GmbH.

Commenting for Locate, Robin Quirk, Director said, “we are delighted to be able to commence our first partnered development program with Heraeus Medical, a company that really understands the needs and opportunities that exist in the regenerative medicine space, as well as having the direct market access to be able to bring these solutions effectively to the patient.”  

 

Source: Press Release Heraeus Medical GmbH

 

10.12.2014

Related articles

Photo

News • Commercial-scale manufacturing

1.4 million grant for resorbable implant development

Medtech company BellaSeno and the Fraunhofer Institute for Production Technology IPT have received a grant totaling EUR 1.4 million for the development of commercial-scale, fully automated additive…

Photo

Oncology and imaging

EC approval for Siemens Healthineers/Varian merger

The European Commission (EC) has concluded its review of the planned merger between Siemens Healthineers AG and Varian Medical Systems, Inc. and approved the transaction subject to certain…

Photo

Sponsored • Keeping up with Progress:

Robotic Evolution Meets Innovative Life Cycle Management

While the debate on the added value of robotics and robot-assisted systems has been in full swing for a while now, the demand for robotic surgery throughout Europe’s medical institutions continues…

Related products

Subscribe to Newsletter